176 related articles for article (PubMed ID: 38132381)
1. Long-Term Follow-Up of Tamoxifen Treatment and the Use of Imaging in Psammocarcinoma: A Case Report, Review of the Literature and Discussion of Diagnostic and Therapeutic Challenges.
Gideonsson I; Israelsson P; Strandberg SN; Ottander U
Curr Oncol; 2023 Nov; 30(12):10260-10271. PubMed ID: 38132381
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
4. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
5. Serous psammocarcinoma of the ovary: CT and MR findings.
Hiromura T; Tanaka YO; Nishioka T; Tomita K
J Comput Assist Tomogr; 2007; 31(3):490-2. PubMed ID: 17538302
[TBL] [Abstract][Full Text] [Related]
6. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m diphosphonate imaging of psammocarcinoma of probable ovarian origin: case report and literature review.
Radin AI; Youssef IM; Quimbo RD; Perone RW; Guerrieri C; Abdel-Dayem HM
Clin Nucl Med; 2005 Jun; 30(6):395-9. PubMed ID: 15891291
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT in serous psammocarcinoma of the ovary.
Dong A; Wang Y; Zuo C
Clin Nucl Med; 2014 May; 39(5):453-5. PubMed ID: 23510884
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
10. Serous psammocarcinoma of the ovary: a case report and review of literature.
Giordano G; Gnetti L; Milione M; Piccolo D; Soliani P
Gynecol Oncol; 2005 Jan; 96(1):259-62. PubMed ID: 15589614
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
13. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
14. Bilateral Serous Psammocarcinoma of Ovary: Rare Variant Low Grade Serous Carcinoma.
Jena SK; Mishra P; Mohapatra V; Singh S
Case Rep Obstet Gynecol; 2015; 2015():531242. PubMed ID: 26557397
[TBL] [Abstract][Full Text] [Related]
15.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
16. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
17. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma.
Kubik-Huch RA; Dörffler W; von Schulthess GK; Marincek B; Köchli OR; Seifert B; Haller U; Steinert HC
Eur Radiol; 2000; 10(5):761-7. PubMed ID: 10823629
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
